Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia

NCT01065038 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

INDUSTRY

Sponsor class

Conditions

Essential Thrombocythaemia

Interventions

DRUG: Anagrelide
DRUG: Hydroxyurea

Sponsor

AOP Orphan Pharmaceuticals AG